JP6069492B2 - C型肝炎ウイルス阻害剤 - Google Patents

C型肝炎ウイルス阻害剤 Download PDF

Info

Publication number
JP6069492B2
JP6069492B2 JP2015509101A JP2015509101A JP6069492B2 JP 6069492 B2 JP6069492 B2 JP 6069492B2 JP 2015509101 A JP2015509101 A JP 2015509101A JP 2015509101 A JP2015509101 A JP 2015509101A JP 6069492 B2 JP6069492 B2 JP 6069492B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
methyl
mmol
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015509101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015515494A (ja
JP2015515494A5 (cg-RX-API-DMAC10.html
Inventor
ロバート マレー マッキネル,
ロバート マレー マッキネル,
ダニエル ディー. ロング,
ダニエル ディー. ロング,
Original Assignee
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー, セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー filed Critical セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー
Publication of JP2015515494A publication Critical patent/JP2015515494A/ja
Publication of JP2015515494A5 publication Critical patent/JP2015515494A5/ja
Application granted granted Critical
Publication of JP6069492B2 publication Critical patent/JP6069492B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015509101A 2012-04-25 2013-04-24 C型肝炎ウイルス阻害剤 Expired - Fee Related JP6069492B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261637956P 2012-04-25 2012-04-25
US61/637,956 2012-04-25
US201361773977P 2013-03-07 2013-03-07
US61/773,977 2013-03-07
PCT/US2013/037934 WO2013163270A1 (en) 2012-04-25 2013-04-24 Hepatitis c virus inhibitors

Publications (3)

Publication Number Publication Date
JP2015515494A JP2015515494A (ja) 2015-05-28
JP2015515494A5 JP2015515494A5 (cg-RX-API-DMAC10.html) 2016-04-21
JP6069492B2 true JP6069492B2 (ja) 2017-02-01

Family

ID=48227586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015509101A Expired - Fee Related JP6069492B2 (ja) 2012-04-25 2013-04-24 C型肝炎ウイルス阻害剤

Country Status (7)

Country Link
US (2) US9066944B2 (cg-RX-API-DMAC10.html)
EP (1) EP2850072B1 (cg-RX-API-DMAC10.html)
JP (1) JP6069492B2 (cg-RX-API-DMAC10.html)
CN (1) CN104302636B (cg-RX-API-DMAC10.html)
CA (1) CA2869908C (cg-RX-API-DMAC10.html)
ES (1) ES2599665T3 (cg-RX-API-DMAC10.html)
WO (1) WO2013163270A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2850075T (lt) * 2012-04-25 2017-05-10 Theravance Biopharma R&D Ip, Llc Piperazino-piperidino junginiai, kaip hepatito c viruso inhibitoriai
GB202013383D0 (en) * 2020-08-26 2020-10-07 Givaudan Sa Process

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
WO2010094977A1 (en) * 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
US20120040977A1 (en) 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
SG176015A1 (en) 2009-05-13 2011-12-29 Gilead Sciences Inc Antiviral compounds
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031904A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA201201031A1 (ru) 2010-01-25 2013-02-28 Энанта Фармасьютиклз, Инк. Ингибиторы вируса гепатита с
MA34147B1 (fr) 2010-03-09 2013-04-03 Merck Sharp & Dohme Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
KR20140045903A (ko) * 2010-08-04 2014-04-17 브리스톨-마이어스 스큅 컴퍼니 C형 간염 바이러스 억제제
EP2603080A4 (en) * 2010-08-12 2014-01-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
CA2814534A1 (en) 2010-11-04 2012-05-10 Theravance, Inc. Novel inhibitors of hepatitis c virus
AR088630A1 (es) * 2011-11-03 2014-06-25 Theravance Inc Inhibidores del virus de la hepatitis c
WO2013165796A1 (en) * 2012-05-03 2013-11-07 Theravance, Inc. Crystalline form of a pyridyl-piperazinyl hepatitis c virus inhibitor

Also Published As

Publication number Publication date
CA2869908C (en) 2018-02-20
JP2015515494A (ja) 2015-05-28
CA2869908A1 (en) 2013-10-31
CN104302636B (zh) 2017-03-29
US9365549B2 (en) 2016-06-14
EP2850072B1 (en) 2016-08-31
CN104302636A (zh) 2015-01-21
US9066944B2 (en) 2015-06-30
US20130287731A1 (en) 2013-10-31
US20150252023A1 (en) 2015-09-10
WO2013163270A1 (en) 2013-10-31
EP2850072A1 (en) 2015-03-25
ES2599665T3 (es) 2017-02-02

Similar Documents

Publication Publication Date Title
JP6082747B2 (ja) フラグメント{2−[4−(ビフェニル−4−イル)−1h−イミダゾ−2−イル]ピロリジン−1−カルボニルメチル}アミンを含む棒状c型肝炎ウイルス阻害剤
JP5891235B2 (ja) C型肝炎ウイルスの新規阻害剤
JP6069491B2 (ja) C型肝炎ウイルス阻害剤としてのピペラジン−ピペリジン化合物
US9365549B2 (en) Hepatitis C virus inhibitors
NZ623846B2 (en) Rod-like hepatitis c virus inhibitors containing the fragment {2-[4-(bi phenyl-4-yl) -1h-imidazo-2-yl] pyrrolidine-1-carbonlymethyl} amine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160829

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161226

R150 Certificate of patent or registration of utility model

Ref document number: 6069492

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees